Fusion Antibodies and Eurofins partner to deliver a complete antibody development pipeline

合作抗体
Antibody discovery company Fusion Antibodies has entered into a commercial collaboration with drug discovery products supplier Eurofins on a partnership designed to help researchers bring new therapeutic antibodies to market. Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that together they can provide a complete workflow solution for busy researchers. This includes Fusion Antibodies services for antibody generation, characterization, sequencing, engineering and expression, and Eurofins Discovery’s in vivo and in vitro services, such as efficacy models, bioanalytical services, biomarker development, phenotypic assays and safety assessment. The collaboration between Fusion Antibodies and Eurofins Discovery will last for an initial two-year period and is a commitment to provide world-class scientific expertise, next-generation technology, and guidance to accelerate the delivery of the best possible antibody against a broad range of targets and therapeutic areas into the clinic. Commenting on the partnership, Dr Richard Jones, CEO of Fusion Antibodies, said: “We are delighted to enter into this commercial collaboration with Eurofins which leverages the respective expertise of both partners, delivering on both our strategic objectives as well as providing a full client service package. Eurofins is an established global provider of testing and laboratory services, and this partnership is a natural fit with Fusion’s mission to enable pharmaceutical and diagnostic companies to develop innovative products in the most efficient and cost-effective way.” Dr Julie Gormley, Business Development Director of Fusion Antibodies, said: “This partnership brings together two world leaders in their respective fields and will enable scientists to focus on their research while our services ensure efficient and robust results. I look forward to working closely with colleagues at Eurofins Discovery throughout 2021 and beyond.”
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。